What are the latest findings on Amgen's MariTide obesity drug?

Recent studies show MariTide helps patients maintain weight loss and also lowers blood sugar in Type 2 diabetes patients.

How does Amgen's MariTide compare to Wegovy or Zepbound?

MariTide offers potential for less frequent dosing, such as monthly or quarterly, compared to the weekly injections of Wegovy and Zepbound.

Can Amgen's MariTide help with Type 2 diabetes?

Yes, a study indicated that MariTide achieved significant reductions in HbA1c and weight in Type 2 diabetes patients.

Home / Health / Amgen's MariTide Maintains Weight Loss, Improves Diabetes

Amgen's MariTide Maintains Weight Loss, Improves Diabetes

13 Jan

•

Summary

MariTide demonstrated sustained weight loss in patients in a second study.
The drug also significantly reduced blood sugar in Type 2 diabetes patients.
Amgen's MariTide offers less frequent dosing compared to current market leaders.

Amgen's MariTide Maintains Weight Loss, Improves Diabetes

Amgen's experimental obesity drug, MariTide, has demonstrated significant potential in recent clinical studies. An extended trial indicated that patients successfully maintained substantial weight loss achieved in earlier phases. This suggests MariTide could offer a valuable option for long-term weight management.

The drug also showed promise in a separate mid-stage trial involving patients with Type 2 diabetes. Results from this study revealed that MariTide led to clinically meaningful reductions in both blood sugar levels, measured by HbA1c, and overall body weight.

Amgen emphasized MariTide's distinct advantage in dosing frequency, positioning it as a potential competitor to current weekly injection weight-loss medications. The company is actively pursuing further development through Phase 3 trials to confirm these promising findings.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.